MYC-Hyperactivated Osteosarcoma Models Exhibit Resistance to Cabozantinib plus TIGIT Blockade
Sarah S. Kappa, Tajhal Patel, Bikesh Kumar Nirala, Lyazat Kurenbekova, Ryan Lane Shuck, Jason Todd Yustein
This study evaluates the efficacy of cabozantinib plus TIGIT blockade in osteosarcoma models, finding improved outcomes in p53-driven tumors but resistance in MYC-hyperactivated models due to myeloid recruitment and ECM remodeling.
bioRxiv · Sep 26, 2026 · PreprintCancer Biology